NYSE:ADCT ADC Therapeutics Q3 2026 Earnings Results & Report $1.58 -0.10 (-5.69%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. ADC Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.16 versus the -$0.2125 consensus estimate, while revenue of $21.72 million topped the $18.69 million estimate by $3.02 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call8:30 AM ET ADC Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.2125Beat/MissBeat by +$0.0525One Year Ago EPS-$0.30EPS Beat Rate6 of last 8 quartersADC Therapeutics Revenue ResultsActual Revenue$21.72 millionExpected Revenue$18.69 millionBeat/MissBeat by +$3.02 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ADC Therapeutics Q3 2026 Earnings FAQ Did ADC Therapeutics beat earnings estimates for Q3 2026? ADC Therapeutics (NYSE:ADCT) reported earnings of -$0.16 per share for Q3 2026, beating the consensus estimate of -$0.2125. The report was announced on Monday, November 9, 2026. What was ADC Therapeutics' revenue for Q3 2026? ADC Therapeutics reported revenue of $21.72 million for Q3 2026, against a consensus estimate of $18.69 million. ADC Therapeutics Earnings HeadlinesADC Therapeutics' Revenue Growth Outlook Remains Unclear, RBC Capital Markets Says5 minutes ago | marketscreener.comMADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9 at 1:52 PM | marketscreener.comMEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 10 at 1:00 AM | Behind the Markets (Ad)ADC Therapeutics Q3 Product Revenue Rises 33%; Cash Runway Extends Into 2029; Stock DownNovember 9 at 1:52 PM | rttnews.comADC Therapeutics Q3 2026: ZYNLONTA Drives a Fourth Straight BeatNovember 9 at 8:51 AM | 247wallst.comADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational UpdatesNovember 9 at 7:30 AM | prnewswire.comSee More ADC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your email. Email Address About ADC TherapeuticsADC Therapeutics (NYSE:ADCT) (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue. The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. ADC Therapeutics has also developed additional investigational ADC candidates targeting blood cancers and solid tumors, including programs designed to address diseases such as lymphoma and other hematologic malignancies. ADC Therapeutics was founded in 2011 and has historically operated as an international biotechnology company with a presence in Switzerland and the United States. Its activities include research, clinical development, regulatory work and commercialization of oncology therapies. The company’s programs are intended for patients in major global pharmaceutical markets, although product availability and development status vary by geography and regulatory approval.View ADC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
